Our drive to transform possibilities for patients fuels our bold approach.

How do we do better by patients? By striving to fundamentally change the way urothelial and specialty cancers are treated. Advances in urothelial cancers have historically been limited. For decades, patients have received the standard of care, which is often invasive or radical surgery. It’s because of these patients that UroGen exists. We believe patients deserve better.

UroGen is at the forefront of what we see as a transformative shift in urothelial and specialty cancers to treat patients by nonsurgical means. This paradigm shift was demonstrated with the launch of our first commercial product in 2020: JELMYTO^® (mitomycin) for pyelocalyceal solution, the first and only FDA-approved nonsurgical treatment of its kind. JELMYTO uses our novel RTGel™ reverse-thermal hydrogel technology to offer an innovative treatment option for patients. Now, UroGen is building upon our innovations in delivery technology by exploring ways to harness the immune system to fight solid tumors in urothelial and specialty cancers.

As we move forward, UroGen will continue our focus on fundamentally changing the treatment paradigm from surgical care and disease management to noninvasive therapeutic options for some of the most devastating cancers. We invite you to learn about UroGen, our technological innovations, and our innovative pipeline, which reflects our vision of shaping the future of patient care.

Warm regards,

Chief Executive Officer